The value of a panel of autoantibodies for predicting the activity of lupus nephritis at time of renal biopsy

Gabriella Moroni, Silvana Quaglini, Antonella Radice, Barbara Trezzi, Francesca Raffiotta, Piergiorgio Messa, Renato Alberto Sinico, Gabriella Moroni, Silvana Quaglini, Antonella Radice, Barbara Trezzi, Francesca Raffiotta, Piergiorgio Messa, Renato Alberto Sinico

Abstract

Few studies have correlated serum biomarkers with renal histology, the gold standard for renal activity, in lupus nephritis (LN). We tested a panel of autoantibodies and complement at the time of kidney biopsy and after treatment. Anti-dsDNA, anti-nucleosome, anti-ribosome P, and anti-C1q antibodies and C3/C4 were measured in 107 patients with LN at the time of renal biopsy and after 6-12 months and were correlated with clinical/histological parameters. At multivariate analysis, high titers of anti-C1q antibodies or of anti-dsDNA antibodies (P = 0.005, OR = 8.67, CI: 2.03-37.3) were the independent predictors that discriminate proliferative from nonproliferative LN. All the immunological parameters, except anti-ribosome, showed a significant correlation with activity index but not with chronicity index. Only anti-C1q showed a significant correlation with the amount of proteinuria (R = 0.2, P = 0.03). None of the immunological parameters were predictive of remission at 6 and 12 months. We found that anti-C1q alone or in combination with anti-dsDNA emerged as the most reliable test in differentiating proliferative and nonproliferative LN. Anti-C1q was the only test correlated with the clinical presentation of LN. After treatment, the titre of the autoantibodies was significantly reduced, but none was predictive of remission.

References

    1. Cervera R., Khamashta M. A., Font J., et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine. 2003;82(5):299–308. doi: 10.1097/01.md.0000091181.93122.55.
    1. Moroni G., Quaglini S., Maccario M., Banfi G., Ponticelli C. 'Nephritic flares' are predictors of bad long-term renal outcome in lupus nephritis. Kidney International. 1996;50(6):2047–2053. doi: 10.1038/ki.1996.528.
    1. Ravirajan C. T., Rowse L., MacGowan J. R., Isenberg D. A. An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systematic lupus erythematosus: a cross-sectional study. Rheumatology. 2001;40(12):1405–1412. doi: 10.1093/rheumatology/40.12.1405.
    1. Ho A., Magder L. S., Barr S. G., Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis & Rheumatism. 2001;44(10):2342–2349. doi: 10.1002/1529-0131(200110)44:10x003C;2342::aid-art397x0003e;;2-8.
    1. Linnik M. D., Hu J. Z., Heilbrunn K. R., et al. Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis & Rheumatism. 2005;52(4):1129–1137. doi: 10.1002/art.20980.
    1. Esdaile J. M., Abrahamowicz M., Joseph L., MacKenzie T., Li Y., Danoff D. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus: why some tests fail. Arthritis and Rheumatism. 1996;39(3):370–378. doi: 10.1002/art.1780390304.
    1. Bigler C., Lopez-Trascasa M., Potlukova E., et al. Antinucleosome antibodies as a marker of active proliferative lupus nephritis. The American Journal of Kidney Diseases. 2008;51(4):624–629. doi: 10.1053/j.ajkd.2007.10.041.
    1. Bizzaro N., Villalta D., Giavarina D., Tozzoli R. Are anti-nucleosome antibodies a better diagnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis. Autoimmunity Reviews. 2012;12(2):97–106. doi: 10.1016/j.autrev.2012.07.002.
    1. Siegert C. E. H., Daha M. R., Tseng C. M. E. S., Coremans I. E. M., van Es L. A., Breedveld F. C. Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. Annals of the Rheumatic Diseases. 1993;52(12):851–856. doi: 10.1136/ard.52.12.851.
    1. Trendelenburg M., Marfurt J., Gerber I., Tyndall A., Schifferli J. A. Lack of occurrence of severe lupus nephritis among anti-C1q autoantibody-negative patients. Arthritis & Rheumatism. 1999;42(1):187–188. doi: 10.1002/1529-0131(199901)42:1x003C;187::aid-anr24x0003e;;2-u.
    1. Sinico R. A., Radice A., Ikehata M., et al. Anti-C1q autoantibodies in lupus nephritis: prevalence and clinical significance. Annals of the New York Academy of Sciences. 2005;1050:193–200. doi: 10.1196/annals.1313.020.
    1. Marto N., Bertolaccini M. L., Calabuig E., Hughes G. R. V., Khamashta M. A. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Annals of the Rheumatic Diseases. 2005;64(3):444–448. doi: 10.1136/ard.2004.024943.
    1. Coremans I. E. M., Spronk P. E., Bootsma H., et al. Changes in antibodies to C1q predict renal relapses in systemic lupus erythematosus. American Journal of Kidney Diseases. 1995;26(4):595–601. doi: 10.1016/0272-6386(95)90595-2.
    1. Moroni G., Trendelenburg M., Del Papa N., et al. Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. The American Journal of Kidney Diseases. 2001;37(3):490–498. doi: 10.1053/ajkd.2001.22071.
    1. Akhter E., Burlingame R. W., Seaman A. L., Magder L., Petri M. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus. 2011;20(12):1267–1274. doi: 10.1177/0961203311411597.
    1. Moroni G., Radice A., Giammarresi G., et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Annals of the Rheumatic Diseases. 2009;68(2):234–237. doi: 10.1136/ard.2008.094508.
    1. Hochberg M. C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis and rheumatism. 1997;40(9):p. 1725.
    1. Weening J. J., D’Agati V. D., Schwartz M. M., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Journal of the American Society of Nephrology. 2004;15(2):241–250.
    1. Austin H. A., III, Boumpas D. T., Vaughan E. M., Balow J. E. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney International. 1994;45(2):544–550. doi: 10.1038/ki.1994.70.
    1. Andreoli L., Pregnolato F., Burlingame R. W., et al. Antinucleosome antibodies in primary antiphospholipid syndrome: a hint at systemic autoimmunity? Journal of Autoimmunity. 2008;30(1-2):51–57. doi: 10.1016/j.jaut.2007.11.004.
    1. Mok C. C., Ho L. Y., Leung H. W., Wong L. G. Performance of anti-C1q, antinucleosome, and anti-dsDNA antibodies for detecting concurrent disease activity of systemic lupus erythematosus. Translational Research. 2010;156(6):320–325. doi: 10.1016/j.trsl.2010.07.009.
    1. Mosca M., Chimenti D., Pratesi F., et al. Prevalence and clinico-serological correlations of anti-α-enolase, anti-C1q, and anti-dsDNA antibodies in patients with systemic lupus erythematosus. The Journal of Rheumatology. 2006;33(4):695–697.
    1. Julkunen H., Ekblom-Kullberg S., Miettinen A. Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4. Rheumatology International. 2012;32(8):2445–2451. doi: 10.1007/s00296-011-1962-3.
    1. Trendelenburg M., Lopez-Trascasa M., Potlukova E., et al. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrology Dialysis Transplantation. 2006;21(11):3115–3121. doi: 10.1093/ndt/gfl436.
    1. Yang X.-W., Tan Y., Yu F., Zhao M.-H. Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis. Nephrology Dialysis Transplantation. 2012;27(9):3552–3559. doi: 10.1093/ndt/gfs179.
    1. Fang Q.-Y., Yu F., Tan Y., et al. Anti-C1q antibodies and IgG subclass distribution in sera from Chinese patients with lupus nephritis. Nephrology Dialysis Transplantation. 2009;24(1):172–178. doi: 10.1093/ndt/gfn453.
    1. Grootscholten C., Dieker J. W. C., McGrath F. D., et al. A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone. Annals of the Rheumatic Diseases. 2007;66(5):693–696. doi: 10.1136/ard.2006.065425.
    1. Matrat A., Veysseyre-Balter C., Trolliet P., et al. Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares. Lupus. 2011;20(1):28–34. doi: 10.1177/0961203310379871.
    1. Oelzner P., Deliyska B., Fünfstück R., Hein G., Herrmann D., Stein G. Anti-C1q antibodies and antiendothelial cells antibodies in systemic lupus erythematosus—relationship with disease activity and renal involvement. Clinical Rheumatology. 2003;22(4-5):271–278. doi: 10.1007/s10067-003-0724-3.
    1. Kumar A., Gupta R., Varghese T., Pande R. M., Singal V. K., Garg O. P. Anti-C1q antibody as a marker of disease activity in systemic lupus erythematosus. Indian Journal of Medical Research. 1999;110:190–193.
    1. Meyer O. C., Nicaise-Roland P., Cadoudal N., et al. Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus. Arthritis Research & Therapy. 2009;11(3, article R87) doi: 10.1186/ar2725.
    1. Seelen M. A., Trouw L. A., Daha M. R. Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. Current Opinion in Nephrology and Hypertension. 2003;12(6):619–624. doi: 10.1097/00041552-200311000-00008.
    1. Mahler M., van Schaarenburg R. A., Trouw L. A. Anti-C1q autoantibodies, novel tests, and clinical consequences. Frontiers in Immunology. 2013;4, article 117 doi: 10.3389/fimmu.2013.00117.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever